Bionano Genomics, Inc. (BNGO) Stock

Bionano Genomics, Inc. (BNGO) is a Technology stock trading at $1.17 (as of 2026-06-18), with a market capitalization of $3.74M and a trailing P/E of -0.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Bionano Genomics provides genome analysis software and supporting products, including Saphyr for optical genome mapping–based structural variation analysis and NxClinical for interpreting genomic variants from microarray and next-generation sequencing data, along with related instruments, consumables, and computational resources. It also offers laboratory and testing services such as chromosomal microarray, Fragile X, exome sequencing, and EpiPanelDx, serving clinical and research users.

Valuation — source: SEC EDGAR (first-party)
Price	$1.17
Market Cap	$3.74M
P/E Ratio	-0.3
EV / EBITDA	-0.4
Price / Book	0.36
Price / Sales	0.46
DCF Value (model)	$-24.68
DCF Upside vs Price	-2209.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$28.51M
Net Margin	-92.6%
Return on Equity	-84.3%
Current Ratio	1.84
Revenue Growth (YoY)	-7.4%
EPS Growth (YoY)	-94.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	-14.17 (distress)

Valuation vs Sector & Industry
Stock P/E	-0.3
Sector P/E (Technology)	32.0
Industry P/E (Measuring & Control Equipment)	60.0
vs Sector	-100.8%
vs Industry	-100.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	GSA CAPITAL PARTNERS LLP ($413000.00)
Institutional Holders Tracked	10

Company
Sector	Technology
Industry	Measuring & Control Equipment
CEO	Robert Erik Holmlin
Employees	98
Country	US
IPO Date	2018-08-21

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.